Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche (RHHBY) AD Study Failure Puts Spotlight on BIIB & Others

by Zacks Equity Research

Roche's (RHHBY) gantenerumab study for early Alzheimer's disease (AD) fails and puts focus on other companies like BIIB, LLY and PRTA.

Halozyme's (HALO) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Halozyme's (HALO) earnings and revenues beat estimates for the third quarter of 2022.

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

Amgen (AMGN) Beats on Q3 Earnings & Sales, Tweaks 2022 View

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for earnings and sales. It tightens previously issued revenue and adjusted earnings guidance ranges.

    Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates

    by Zacks Equity Research

    Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.

    Regeneron (REGN) Q3 Earnings & Sales Beat on Eylea, Dupixent

    by Zacks Equity Research

    Regeneron (REGN) tops earnings and sales estimates for the third quarter, driven by its lead drug Eylea and profits from the asthma drug, Dupixent. However, earnings decline year over year.

    Blueprint Medicines (BPMC) Q3 Earnings & Revenues Top Mark

    by Zacks Equity Research

    Blueprint Medicines' (BPMC) earnings and revenues trump estimates for the third quarter of 2022. The company lowers product revenue guidance for Ayvakit.

    Seagen's (SGEN) Q3 Earnings Miss, Revenues Surpass Estimates

    by Zacks Equity Research

    Seagen (SGEN) reports a wider-than-expected loss in the third quarter of 2022 while its revenues beat estimates. The company raises total revenue guidance for 2022.

    Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.

    Will AbbVie's Immunology Drugs Continue to Drive Q3 Earnings?

    by Zacks Equity Research

    AbbVie's (ABBV) third-quarter performance is expected to reflect the impact of strong demand for immunology and aesthetics products.

    Biogen (BIIB) Beats on Q3 Earnings & Sales, Raises 2022 Outlook

    by Zacks Equity Research

    Biogen (BIIB) beats third-quarter estimates for earnings and sales. Stock rises in pre-market as management raises the company's full-year 2022 financial guidance.

    Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates

    by Zacks Equity Research

    Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.

    The Zacks Analyst Blog Highlights J&J, Roche, Eli Lilly and AbbVie

    by Zacks Equity Research

    J&J, Roche, Eli Lilly and AbbVie are part of The Zacks top Analyst Blog.

    AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    AbbVie (ABBV) third-quarter performance will likely reflect the impact of strong demand for immunology and aesthetics franchises. Investors will also enquire about ABBV's plans to counter Humira LOE.

    Biogen (BIIB) to Report Q3 Earnings: Here's What to Expect

    by Zacks Equity Research

    Biogen's (BIIB) sales in the third quarter are likely to have been hurt by lower sales of Tecfidera and Spinraza.

      Kinjel Shah headshot

      Pharma Stock Roundup: JNJ Q3 Earnings Beat, RHHBY Sales Weak, LLY, ABBV Ink M&A Deals

      by Kinjel Shah

      J&J (JNJ) beats earnings and sales estimates for the third quarter. Eli Lilly (LLY) and AbbVie (ABBV) announce small acquisitions.

      PTC Therapeutics (PTCT) Halts Huntington's Disease Study in US

      by Zacks Equity Research

      The FDA requests additional data to allow PTC Therapeutics (PTCT) to continue enrollment in its phase II PIVOT-HD study evaluating PTC518 for treating Huntington's disease in the United States. Stock down.

      Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales

      by Zacks Equity Research

      Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.

      Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?

      by Zacks Equity Research

      Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.

      Will Seagen's (SGEN) Portfolio of Drugs Help Combat Rivalry?

      by Zacks Equity Research

      Seagen (SGEN) expects its portfolio of marketed drugs, which are approved for various cancer indications, to generate incremental sales and combat stiff competition.

      Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?

      by Zacks Equity Research

      Regeneron's (REGN) top line is affected by negligible sales from REGEN-COV while lead drug Eylea faces stiff competition.

      Can Biogen (BIIB) Navigate Multiple Challenges & Grow Again?

      by Zacks Equity Research

      Most of Biogen's (BIIB) key drugs are facing declining sales. Despite these challenges, we are hopeful that potential new product launches such as lecanemab, zuranolone and additional biosimilars can help revive growth.

      Sarepta (SRPT) Seeks FDA Nod for DMD Gene Therapy Candidate

      by Zacks Equity Research

      If approved, Sarepta's (SRPT) SRP-9001 will be the first gene therapy for DMD indication in the United States. The company seeks approval for gene therapy under the accelerated pathway.

      NVS vs. RHHBY: Which Stock Should Value Investors Buy Now?

      by Zacks Equity Research

      NVS vs. RHHBY: Which Stock Is the Better Value Option?

      Ekta Bagri headshot

      LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

      by Ekta Bagri

      The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.